Keymed Biosciences (FRA:64Z) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:64Z Keymed Biosciences Inc FRA:64Z
44 GF Score
Price €8.45
GF Value €18.50
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Keymed Biosciences Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Keymed Biosciences Valuation Rank Related Terms

FRA:64Z
44GF Score
Keymed Biosciences Inc FRA:64Z
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Keymed Biosciences (FRA:64Z) Overvalued in 2026?

Based on GuruFocus' analysis, Keymed Biosciences stock appears to be undervalued. The current stock price of €8.45 is trading 54.3% below its estimated GF Value™ of €18.50. GuruFocus considers Keymed Biosciences to be Possible Value Trap.

Key valuation signals for FRA:64Z:

  • Valuation Rank:
  • GF Value™: €18.50 vs. price of €8.45 (54.3% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the FRA:64Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Keymed Biosciences Business Description

Other Exchanges 02162:Hong Kong
Address No. 669 Fenghuang Road, Shuangliu District, Chengdu, Sichuan, CHN, 610219
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
44GF Score

Get the complete analysis for FRA:64Z

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.45
Price
€18.50
GF Value